Compare ARCT & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | ATRO |
|---|---|---|
| Founded | 2013 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 3.5B |
| IPO Year | 2019 | 1995 |
| Metric | ARCT | ATRO |
|---|---|---|
| Price | $15.80 | $67.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $24.11 | ★ $86.00 |
| AVG Volume (30 Days) | ★ 1.5M | 472.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 276.09 |
| EPS | N/A | ★ 1.31 |
| Revenue | $82,031,000.00 | ★ $862,128,000.00 |
| Revenue This Year | N/A | $14.92 |
| Revenue Next Year | $12.77 | $8.81 |
| P/E Ratio | ★ N/A | $56.47 |
| Revenue Growth | N/A | ★ 8.39 |
| 52 Week Low | $5.50 | $39.14 |
| 52 Week High | $24.14 | $99.89 |
| Indicator | ARCT | ATRO |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 40.40 |
| Support Level | $6.47 | $63.78 |
| Resistance Level | $17.75 | $73.65 |
| Average True Range (ATR) | 1.33 | 2.71 |
| MACD | -0.30 | -0.59 |
| Stochastic Oscillator | 38.45 | 13.24 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.